Transcriptional profiling of gene expression changes in immune cells of human subjects treated with Varilumab

This study evaluatated transcriptomic changes in RNA isolated from whole-blood samples from 12 patients receiving different doses of Varlilumab at several different time points following treatment. The aim of this study was to determine the extent to which expression of inflammatory molecules changes over time in response to treatment with Varilumab, a fully human monoclonal antibody (mAb) that targets CD27. Total RNA from whole-blood samples was isolated before treatment with Varilumab and 1, 7, and 28 days after treatment. The data set comprises 48 samples taken from 12 human subjects at 4 time points: Study Day (SD) 1, which is pre-treatment, SD2, SD8, and SD29. 5 doses of Varilumab were used--0.1 mg, 0.3 mg, 1 mg, 3 mg, and 10 mg. Two subjects received 0.1 mg, 2 subjects 0.3 mg, 3 subjects 1mg, 3 subjects 3mg, and 2 subjects 10 mg.